Literature DB >> 15655244

Oral antihyperglycemic therapy for type 2 diabetes mellitus.

Alice Y Y Cheng1, I George Fantus.   

Abstract

Diabetes mellitus is a chronic disease that is growing in prevalence worldwide. Pharmacologic therapy is often necessary to achieve optimal glycemic control in the management of diabetes. Orally administered antihyperglycemic agents (OHAs) can be used either alone or in combination with other OHAs or insulin. The number of available OHAs has increased significantly in the last decade, which translates into more therapeutic options and complex decision-making for physicians. This review article is designed to help with these decisions. We review the mechanism of action, efficacy and side effects of the different classes of OHAs (alpha-glucosidase inhibitors, biguanides, insulin secretagogues, insulin sensitizers and intestinal lipase inhibitor) and discuss the current recommendations for their use.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15655244      PMCID: PMC543986          DOI: 10.1503/cmaj.1031414

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  75 in total

1.  Effects of gliclazide versus metformin on the clinical profile and lipid peroxidation markers in type 2 diabetes.

Authors:  D Tessier; P Maheux; A Khalil; T Fülöp
Journal:  Metabolism       Date:  1999-07       Impact factor: 8.694

Review 2.  Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance.

Authors:  A Virkamäki; K Ueki; C R Kahn
Journal:  J Clin Invest       Date:  1999-04       Impact factor: 14.808

3.  Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.

Authors:  I M Stratton; A I Adler; H A Neil; D R Matthews; S E Manley; C A Cull; D Hadden; R C Turner; R R Holman
Journal:  BMJ       Date:  2000-08-12

4.  Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide.

Authors:  H Klepzig; G Kober; C Matter; H Luus; H Schneider; K H Boedeker; W Kiowski; F W Amann; D Gruber; S Harris; W Burger
Journal:  Eur Heart J       Date:  1999-03       Impact factor: 29.983

5.  Effect of intensive therapy on early macrovascular disease in young individuals with type 1 diabetes. A systematic review and meta-analysis.

Authors:  M L Lawson; H C Gerstein; E Tsui; B Zinman
Journal:  Diabetes Care       Date:  1999-03       Impact factor: 19.112

Review 6.  Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.

Authors:  Shelley R Salpeter; Elizabeth Greyber; Gary A Pasternak; Edwin E Salpeter
Journal:  Cochrane Database Syst Rev       Date:  2010-04-14

7.  Repaglinide versus glyburide: a one-year comparison trial.

Authors:  T Marbury; W C Huang; P Strange; H Lebovitz
Journal:  Diabetes Res Clin Pract       Date:  1999-03       Impact factor: 5.602

8.  Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes.

Authors:  I E Kelly; T S Han; K Walsh; M E Lean
Journal:  Diabetes Care       Date:  1999-02       Impact factor: 19.112

9.  Inhibitory effect of metformin on intestinal glucose absorption in the perfused rat intestine.

Authors:  T Ikeda; K Iwata; H Murakami
Journal:  Biochem Pharmacol       Date:  2000-04-01       Impact factor: 5.858

10.  Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia.

Authors:  M Hanefeld; K P Bouter; S Dickinson; C Guitard
Journal:  Diabetes Care       Date:  2000-02       Impact factor: 19.112

View more
  82 in total

1.  Metformin's contraindications: needed for now.

Authors:  I George Fantus
Journal:  CMAJ       Date:  2005-08-30       Impact factor: 8.262

2.  Effect of thiazolidinediones on lipid profile.

Authors:  Pankaj Madan
Journal:  CMAJ       Date:  2005-08-16       Impact factor: 8.262

3.  Patient characteristics not described.

Authors:  Stanley Lofsky
Journal:  CMAJ       Date:  2006-06-20       Impact factor: 8.262

Review 4.  New anti-hyperglycaemic agents for type 2 diabetes and their effects on diabetic retinopathy.

Authors:  Mercy Saw; Vincent W Wong; I-Van Ho; Gerald Liew
Journal:  Eye (Lond)       Date:  2019-06-21       Impact factor: 3.775

5.  Characterization of different crystal forms of the alpha-glucosidase MalA from Sulfolobus solfataricus.

Authors:  Heidi Asschenfeldt Ernst; Martin Willemoës; Leila Lo Leggio; Gordon Leonard; Paul Blum; Sine Larsen
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2005-11-05

6.  The influence of drug solubility and sampling frequency on metformin and glibenclamide release from double-layered particles: experimental analysis and mathematical modelling.

Authors:  T Shams; F Brako; S Huo; A H Harker; U Edirisinghe; M Edirisinghe
Journal:  J R Soc Interface       Date:  2019-06-26       Impact factor: 4.118

7.  Evaluation of the anti-osteoporotic effects of metformin and sitagliptin in postmenopausal diabetic women.

Authors:  Sahar Kamal Hegazy
Journal:  J Bone Miner Metab       Date:  2014-03-15       Impact factor: 2.626

8.  Effect of oleanolic acid on small intestine morphology and enzymes of glutamine metabolism in diabetic rats.

Authors:  Murtala Bindawa Isah; Bubuya Masola
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2017-11-01

Review 9.  Octreotide's role in the management of sulfonylurea-induced hypoglycemia.

Authors:  Patrick P Dougherty; Wendy Klein-Schwartz
Journal:  J Med Toxicol       Date:  2010-06

Review 10.  Vascular endothelium dysfunction: a conservative target in metabolic disorders.

Authors:  Shalini Jamwal; Saurabh Sharma
Journal:  Inflamm Res       Date:  2018-01-25       Impact factor: 4.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.